3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Suspended
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Neoplasms
27
Colorectal Neoplasms
20
Breast Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
13
Neoplasm Metastasis
12
Lung Neoplasms
11
Stomach Neoplasms
10
Leukemia, Myeloid, Acute
10
Melanoma
9
Lymphoma, Non-Hodgkin
8
Small Cell Lung Carcinoma
6
Recurrence
6
Liver Neoplasms
6
Leukemia
6
Head and Neck Neoplasms
6
Fallopian Tube Neoplasms
6
Prostatic Neoplasms
5
Glioblastoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Gastrointestinal Neoplasms
4
Uterine Cervical Neoplasms
3
Interventions
10-propargyl-10-deazaaminopterin
11
Cyclophosphamide
8
Prednisone
7
Vincristine
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Doxorubicin
6
belinostat
5
Brentuximab Vedotin
5
romidepsin
4
mogamulizumab
4
darinaparsin
4
Vitamin B 12
4
Gemcitabine
4
Folic Acid
4
selinexor
3
denileukin diftitox
3
Nivolumab
3
Injections
3
Bendamustine Hydrochloride
3
tislelizumab
2
tipifarnib
2
tenalisib
2
duvelisib
2
Rituximab
2
Lenalidomide
2
HBI-8000
2
Fenretinide
2
E7777 fusion protein
2
AFM13
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Peripheral
×
Drug Therapy
×
Clear all
NCT05138458
2023-11-13
IMAGINE
Myeloid Therapeutics
Phase 1/2
Suspended
40 enrolled